WS #16509
Eli Lilly reported third-quarter earnings that blew past estimates, with revenue up 39% year-over-year, driven by surging demand for its GLP-1 weight-loss drugs Zepbound and Mounjaro. The company hiked its sales outlook, reinforcing its dominance in the obesity treatment market. This performance highlights the continued strength of the healthcare sector's defensive growth narrative, as LLY's pricing power and demand resilience stand in contrast to the margin pressures facing other sectors. The stock is up over 4% in pre-market trading.
GLP-1 Demand Surge
Eli Lilly reported third-quarter earnings that blew past estimates, with revenue up 39% year-over-year, driven by surging demand for its GLP-1 weight-loss drugs Zepbound and Mounjaro. The company hiked its sales outlook, reinforcing its dominance in the obesity treatment market. This performance highlights the continued strength of the healthcare sector's defensive growth narrative, as LLY's pricing power and demand resilience stand in contrast to the margin pressures facing other sectors. The stock is up over 4% in pre-market trading.